Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.

ABSTRACT:

Background

Population-adjusted indirect comparison using parametric Simulated Treatment Comparison (STC) has had limited application to survival outcomes in unanchored settings. Matching-Adjusted Indirect Comparison (MAIC) is commonly used but does not account for violation of proportional hazards or enable extrapolations of survival. We developed and applied a novel methodology for STC in unanchored settings. We compared overall survival (OS) and progression-free survival (PFS) of lenvatinib plus pembrolizumab (LEN + PEM) against nivolumab plus ipilimumab (NIVO + IPI), pembrolizumab plus axitinib (PEM + AXI), avelumab plus axitinib (AVE + AXI), and nivolumab plus cabozontanib (NIVO + CABO) in patients with advanced renal cell carcinoma (RCC). Unanchored comparison was necessitated

SUBMITTER: Fawsitt CG 

PROVIDER: S-EPMC11780865 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature